Clinical value of circulating tumour cells in evaluating the efficacy of continuous hepatic arterial infusion among colorectal cancer patients

Abstract

Few studies have been conducted to evaluate the efficacy of HAIC using circulating tumour cells (CTCs). In this study, a total of 100 patients who received HAIC treatment and CTC detection were selected. The results showed that after HAIC treatment, the levels of CTC, carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) decreased. Postoperative progression-free survival (PFS) rates between patients with positive and negative preoperative CTC results, and for CA19-9, CEA were significantly different. The positive rate of CTCs was 61% before chemotherapy and 23% after chemotherapy, and the correlation coefficient between the two was 0.385. Those whose CTC values increased after chemotherapy had shorter PFS rates. CTCs are an independent predictor of recurrence. Patients with CTC-positive results are more susceptible to recurrence. The CTC count in peripheral blood has a close bearing on the postoperative chemotherapy efficacy of patients with CRC and affects patients’ PFS.

Keywords:

• colorectal cancer
• liver metastasis
• hepatic arterial infusion chemotherapy
• circulating tumour cells

Ethics approval and consent to participate

This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of No. 2 Hospital of Baoding. Written informed consent was obtained from all participants.

Author contributions

(I) Conception and design: Zhang EY

(II) Administrative support: Li HF and Liu CY

(III) Provision of study materials or patients: Zhou HK and Liu B

(IV) Collection and assembly of data: Feng CB and Zhang EY

(V) Data analysis and interpretation: Li HF and Zhou HK

(VI) Manuscript writing: All authors

(VII) Final approval of manuscript: All authors

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Consent for publication

The manuscript is not submitted for publication or consideration elsewhere.

Disclosure statement

The authors declare that they have no competing interests.

Additional information

Funding

Not applicable